BioSpace News Archive

GT Molecular, a company providing ultrasensitive PCR assays for wastewater-based epidemiology, cancer and pathogen panels has implemented a highly sensitive, wastewater-based test for hMPXV.

PatientBond, announced today that it has contracted with Vizient, Inc., the largest member-driven health care performance improvement company in the country, to offer digital patient engagement and behavior change programs to Vizient member healthcare organizations for improved clinical and business outcomes.

Checkpoint Surgical announced today the launch of the Checkpoint Edge™ Nerve Cutting Kit, extending the breadth of the company’s intraoperative nerve care portfolio.

UBC, a biopharmaceutical leader providing integrated clinical, safety, and commercialization services, announced that it has acquired Examoto, LLC, a Risk Evaluation and Mitigation Strategy company.

Diagnostic Robotics, a leading provider of Artificial Intelligence & Care Management solutions for Healthcare plans and providers, today announced the closing of a $45M Series B funding round led by StageOne investors, with participation from Mayo Clinic, thus becoming a Mayo Clinic Platform portfolio company.

ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer and Shionogi as shareholders, today announced new efficacy and safety findings from the unblinded period of the HIV Prevention Trials Network (HPTN) 084 trial evaluating cabotegravir long-acting (LA) for pre-exposure prophylaxis (PrEP) in women in sub-Saharan Africa.

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, and the Medicines Patent Pool (MPP) today announced the signing of a new voluntary licensing agreement for patents relating to cabotegravir long-acting (LA) for HIV pre-exposure prophylaxis (PrEP) to help enable access in least developed, low-income, lower middle-income and Sub-Saharan African countries.

DYSIS Medical Inc., an emerging biophotonics company focused on providing innovative cervical mapping technology designed to help healthcare professionals identify precancerous lesions on the cervix, announced the appointment of Chris Arnold as Chief Commercial Officer.

Tallac Therapeutics, Inc., a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer, today announced that the first patient has been dosed with TAC-001 in a Phase 1/2 clinical trial for patients with advanced or metastatic solid tumors.

NervGen Pharma Corp., (TSX-V: NGEN) (OTCQX: NGENF), is pleased to announce the University of Cincinnati and Case Western Reserve University (CWRU) have published a pioneering preclinical study in the peer-reviewed scientific journal Cell Reports demonstrating that NervGen’s proprietary drug, NVG-291-R.